Using this method, we identified two prognostic and TP53 mutation-driven signatures (BRmet50 and PMID18271932Sig33) in breast cancer and one signature (PMID20813035Sig137) specific for prognosis prediction in patients with ER-negative tumors. Here, TP53 is linked to breast cancer.